• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hemorrhage - Pipeline Review, H1 2012 Product Image

Hemorrhage - Pipeline Review, H1 2012

  • Published: June 2012
  • 44 pages
  • Global Markets Direct

Hemorrhage – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hemorrhage - Pipeline Review, H1 2012', provides an overview of the Hemorrhage therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. 'Hemorrhage - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hemorrhage.
- A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hemorrhage Overview
Therapeutics Development
An Overview of Pipeline Products for Hemorrhage
Hemorrhage Therapeutics under Development by Companies
Hemorrhage Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hemorrhage Therapeutics – Products under Development by Companies
Hemorrhage Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hemorrhage Therapeutics Development
Thrombotargets Corporation
QRxPharma Limited
Hemorrhage – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Q8008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TT-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TT-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TT-173 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tranexamic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tranexamic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tranexamic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TT-103MH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG-1960 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transamin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemorrhage Therapeutics – Drug Profile Updates
Hemorrhage Therapeutics - Dormant Products
Hemorrhage – Product Development Milestones
Featured News & Press Releases
Sep 20, 2010: Oxygen Biotherapeutics Amends CRADA With US Navy To Include Preclinical Studies Of Oxycyte For Spinal Cord Injury And Hemorrhagic Shock
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hemorrhage, H1 2012
Products under Development for Hemorrhage – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Thrombotargets Corporation, H1 2012
QRxPharma Limited, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hemorrhage Therapeutics – Drug Profile Updates
Hemorrhage Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hemorrhage, H1 2012
Products under Development for Hemorrhage – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos